奥赛康：公司创新药利厄替尼片纳入国家医保目录

Core Insights - The National Healthcare Security Administration (NHSA) has released the updated National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the Commercial Health Insurance Innovative Drug Catalog for 2025, marking the first time both catalogs are synchronized to enhance the dual-track system of basic and commercial health insurance for innovative drugs [1] Group 1: Drug Catalog Adjustments - A total of 114 new drugs have been added to the insurance catalog, including 50 first-class innovative drugs, while 29 drugs have been removed due to lack of clinical supply or better alternatives [1] - The total number of drugs in the catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [1] - A six-month transition period has been established for drugs removed from the catalog, allowing continued payment at original rates until June 2026 [1] Group 2: Impact of Aoshikang's Drug Inclusion - Aoshikang's innovative drug Aoxin (generic name: Liratinib) has been successfully included in the national insurance catalog, significantly reducing the economic burden on lung cancer patients and improving clinical accessibility [2] - Aoxin is a third-generation EGFR-TKI with independent intellectual property rights, showing strong tumor suppression activity and advantages in treating brain metastases, which are common in EGFR-mutant NSCLC patients [2] - The inclusion of Aoxin in the insurance catalog represents a milestone in its development and provides multiple benefits for lung cancer patients, addressing the affordability issue of innovative drugs and enhancing the level of drug security for insured patients [3]